Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.430
-0.310 (-6.54%)
At close: Dec 1, 2025, 4:00 PM EST
4.472
+0.042 (0.94%)
Pre-market: Dec 2, 2025, 8:23 AM EST
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.21 billion as of December 2, 2025. Its market cap has increased by 167.92% in one year.
Market Cap
1.21B
Enterprise Value
985.20M
1-Year Change
167.92%
Ranking
Category
Stock Price
$4.43
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.21B, an increase of 75.76%. That is a compound annual growth rate of 11.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Dec 1, 2025 | 1.21B | 242.25% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 962.96B |
| Johnson & Johnson | 498.53B |
| AbbVie | 402.43B |
| UnitedHealth Group | 298.72B |
| AstraZeneca | 286.85B |
| Merck & Co. | 260.19B |
| Novartis AG | 249.40B |
| Abbott Laboratories | 224.14B |